SITE010-0206

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE010 (ESP) · Dr. Silva
consented 2022-10-19

AEs

Serious

Dropout signal

–

Adverse events

severe serious assessed

Grade 3 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-11-13 (study day 5); relationship: not assessed; serious criteria: hospitalization

moderate assessed

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-11-14 (study day 6); relationship: N

mild assessed

Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-11-17 (study day 9); relationship: Y

mild assessed

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-11-22 (study day 14); relationship: N

mild assessed

Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-11-23 (study day 15); relationship: not assessed

moderate assessed

Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-11-26 (study day 18); relationship: N

moderate assessed

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-12-01 (study day 23); relationship: Y

moderate assessed

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-12-03 (study day 25); relationship: not assessed

mild assessed

Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2022-12-09 (study day 31); relationship: not assessed

Data queries

No data queries.